Following the recent FDA approval of Dermavant’s VTAMA® (tapinarof) cream 1% for the treatment of plaque psoriasis in adults, we are proud to share more about its development process and the successful collaboration between Innovaderm and Dermavant. Tapinarof was discovered by Canadian scientists and its development was initiated by Welichem, a Canadian company. Tapinarof is considered an important piece of Innovaderm’s history as we have been involved in all phases of its clinical development, both as CRO and CRU. Our CRU has been selected to conduct the First-in-Man study back in 2007, and our CRO successfully managed the first of multiple trials using this compound for both atopic dermatitis and psoriasis. Innovaderm’s CRU investigators wrote an article entitled: Tapinarof for Psoriasis and Atopic Dermatitis: 15 Years of Clinical Research, which was recently published in the Journal of the European Academy of Dermatology and Venereology. Click here to read more. To read more on Innovaderm’s implication in all phases of the clinical development of the FDA-approved tapinarof, find our previous press release here.
